The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Key challenges in treating carcinoid and large cell neuroendocrine tumors
Lynnette Fernandez-Cuesta, PhD, International Agency for Research on Cancer (IARC-WHO), Lyon, France, discusses the challenges and complexities involved in studying and treating carcinoid and large cell neuroendocrine tumors, and how researchers are addressing these challenges. Dr Fernandez-Cuesta highlights the limited number of samples available as a major challenge in studying rare challenges, making it less profitable for pharmaceutical companies to develop drugs and challenging to assess treatment benefits. However, efforts are being made, such as creating registries and networks of experts, and increased funding for basic biology and clinical research. In the case of carcinoids, a key limitation is the scarcity of data and financial resources, while for endocrine carcinomas, innovative approaches are needed to understand their progression and identify therapeutic targets. Studying clonal relationships and utilizing tools like supra-carcinomas may offer insights for early intervention and treatment strategies. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
